ScienceGate
Advanced Search
Author Search
Journal Finder
Blog
Sign in / Sign up
ScienceGate
Search
Author Search
Journal Finder
Blog
Sign in / Sign up
Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours
European Journal of Nuclear Medicine and Molecular Imaging
◽
10.1007/s00259-010-1631-x
◽
2010
◽
Vol 38
(2)
◽
pp. 302-311
◽
Cited By ~ 114
Author(s):
Phillip G. Claringbold
◽
Paul A. Brayshaw
◽
Richard A. Price
◽
J. Harvey Turner
Keyword(s):
Phase Ii
◽
Neuroendocrine Tumours
◽
Phase Ii Study
Download Full-text
Related Documents
Cited By
References
A randomised phase II study comparing capecitabine plus streptozocin with or without cisplatin in the treatment of unresectable or metastatic gastroentero-neuroendocrine tumours of the foregut, pancreatic neuroendocrine tumours and neuroendocrine tumours of unknown primary site
http://isrctn.org/>
◽
10.1186/isrctn35124268
◽
2012
◽
Author(s):
Pippa Corrie
Keyword(s):
Phase Ii
◽
Neuroendocrine Tumours
◽
Phase Ii Study
◽
Primary Site
◽
Unknown Primary
◽
Unknown Primary Site
◽
Pancreatic Neuroendocrine Tumours
Download Full-text
Phase II study of everolimus (EVL) and octreotide (OCT) LAR in patients with non-functioning gastrointestinal neuroendocrine tumours (GI-NETs): EVERLAR study
Annals of Oncology
◽
10.1093/annonc/mdw369.29
◽
2016
◽
Vol 27
◽
pp. vi145
Author(s):
J. Capdevila
◽
A. Teulé
◽
J. Barriuso
◽
D. Castellano
◽
C. Lopez
◽
...
Keyword(s):
Phase Ii
◽
Neuroendocrine Tumours
◽
Phase Ii Study
◽
Gastrointestinal Neuroendocrine Tumours
Download Full-text
Phase II study of pazopanib monotherapy in metastatic gastroenteropancreatic neuroendocrine tumours
British Journal of Cancer
◽
10.1038/bjc.2013.470
◽
2013
◽
Vol 109
(6)
◽
pp. 1414-1419
◽
Cited By ~ 47
Author(s):
H K Ahn
◽
J Y Choi
◽
K-M Kim
◽
H Kim
◽
S-H Choi
◽
...
Keyword(s):
Phase Ii
◽
Neuroendocrine Tumours
◽
Phase Ii Study
◽
Gastroenteropancreatic Neuroendocrine Tumours
Download Full-text
Everolimus after hepatic arterial embolisation therapy of metastases from gastrointestinal neuroendocrine tumours: The FFCD 1104-EVACEL-GTE phase II study
European Journal of Cancer
◽
10.1016/j.ejca.2019.09.021
◽
2019
◽
Vol 123
◽
pp. 92-100
Author(s):
Thomas Walter
◽
Come Lepage
◽
Romain Coriat
◽
Emilie Barbier
◽
Guillaume Cadiot
◽
...
Keyword(s):
Phase Ii
◽
Neuroendocrine Tumours
◽
Phase Ii Study
◽
Arterial Embolisation
◽
Gastrointestinal Neuroendocrine Tumours
Download Full-text
718 ORAL Results of a phase II study with sunitinib malate (SU11248) in patients (pts) with advanced neuroendocrine tumours (NETs)
European Journal of Cancer Supplements
◽
10.1016/s1359-6349(05)81013-4
◽
2005
◽
Vol 3
(2)
◽
pp. 204
◽
Cited By ~ 3
Keyword(s):
Phase Ii
◽
Neuroendocrine Tumours
◽
Phase Ii Study
◽
Sunitinib Malate
Download Full-text
A randomised, factorial phase II study to determine the optimal dosing regimen for 68Ga-satoreotide trizoxetan as an imaging agent in patients with gastroenteropancreatic neuroendocrine tumours
Journal of Nuclear Medicine
◽
10.2967/jnumed.121.261936
◽
2021
◽
pp. jnumed.121.261936
Author(s):
Irene Virgolini
◽
Shadfar Bahri
◽
Andreas Kjaer
◽
Henning Gronbaek
◽
Peter Iversen
◽
...
Keyword(s):
Phase Ii
◽
Neuroendocrine Tumours
◽
Phase Ii Study
◽
Imaging Agent
◽
Dosing Regimen
◽
Optimal Dosing
◽
Gastroenteropancreatic Neuroendocrine Tumours
Download Full-text
Antiproliferative effects of lanreotide autogel in patients with progressive, well-differentiated neuroendocrine tumours: a Spanish, multicentre, open-label, single arm phase II study
BMC Cancer
◽
10.1186/1471-2407-13-427
◽
2013
◽
Vol 13
(1)
◽
Cited By ~ 41
Author(s):
Marta Martín-Richard
◽
Bartomeu Massutí
◽
Eva Pineda
◽
Vicente Alonso
◽
Maribel Marmol
◽
...
Keyword(s):
Phase Ii
◽
Neuroendocrine Tumours
◽
Phase Ii Study
◽
Open Label
◽
Antiproliferative Effects
◽
Well Differentiated
◽
Lanreotide Autogel
Download Full-text
2269 [177Lu-DOTA]-D-Phe1-Tyr3-octreotide (177Lu-DOTATOC) for peptide receptor radiotherapy in patients with advanced neuroendocrine tumours: A retrospective phase II study of efficacy and safety
European Journal of Cancer
◽
10.1016/s0959-8049(16)31185-6
◽
2015
◽
Vol 51
◽
pp. S422-S423
Author(s):
R.P. Baum
◽
A.K. Kluge
◽
H.R. Kulkarni
◽
M. Sayeg
◽
U. Schorr-Neufing
◽
...
Keyword(s):
Phase Ii
◽
Neuroendocrine Tumours
◽
Phase Ii Study
◽
Efficacy And Safety
◽
Peptide Receptor
Download Full-text
177Lu-DOTATATE plus 166Ho-radioembolization in patients with neuroendocrine tumours: A single center, prospective, interventional, non-comparative, open label, phase II study (HEPAR PLUS study)
Annals of Oncology
◽
10.1093/annonc/mdz256
◽
2019
◽
Vol 30
◽
pp. v564
Author(s):
A J A T Braat
◽
R. van Rooij
◽
R.C.G. Bruijnen
◽
M N G J A Braat
◽
F. Wessels
◽
...
Keyword(s):
Phase Ii
◽
Neuroendocrine Tumours
◽
Phase Ii Study
◽
Single Center
◽
Open Label
◽
Open Label Phase
Download Full-text
A phase II study of interferon alpha-2a (IFNα) and modulated 5-f1uorouracil (5-FU)in patients (pts) with advanced neuroendocrine tumours (NET)
European Journal of Cancer
◽
10.1016/s0959-8049(97)86145-x
◽
1997
◽
Vol 33
◽
pp. S273
Author(s):
D. Papamlchael
◽
R.T. Penson
◽
M.T. Seymour
◽
P. Wilson
◽
C.J. Gallagher
◽
...
Keyword(s):
Interferon Alpha
◽
Phase Ii
◽
Neuroendocrine Tumours
◽
Phase Ii Study
Download Full-text
Sign in / Sign up
Close
Export Citation Format
Close
Share Document
Close